Product Information
BREO ELLIPTA 50-25 MCG INHALER is a brand product labeled by GlaxoSmithKline LLC, priced at $6.4820 per EA under NDC 00173091610. Its NADAC has been published 124 times since May 22, 2024.
FDA first approved this application on May 10, 2013.
Strength
50; 25 ug/1; ug/1
Manufacturer
GlaxoSmithKline LLCNDC
00173091610
Classification
Brand
Dosage Form
POWDER
Route
RESPIRATORY (INHALATION)
Effective Date
9/23/2026
Active Ingredients
FLUTICASONE FUROATE; VILANTEROL TRIFENATATEApproval Type
New Drug (NDA)
FDA Application
NDA204275FDA Approved
5/10/2013
On Market Since
5/12/2023
Pharmacological Classes
Price Statistics
The NADAC for BREO ELLIPTA 50-25 MCG INHALER has been published 124 times since May 22, 2024, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.
| Current price | $6.4820 per EA |
|---|---|
| All-time high | $6.5164 (Jun 12, 2024) |
| All-time low | $6.4820 (Sep 23, 2026) |
| 52-week high | $6.4931 |
| 52-week low | $6.4820 |
| Median price | $6.4933 |
| Average price | $6.4967 |
| Largest weekly change | -0.1% (Jun 19, 2024) |
| Weeks tracked | 124 |
| Tracking since | May 22, 2024 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the fluticasone furoate and vilanterol trifenatate market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
GlaxoSmithKline LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
fluticasone furoate and vilanterol trifenatate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Corticosteroid class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of BREO ELLIPTA 50-25 MCG INHALER?
The current National Average Drug Acquisition Cost (NADAC) for BREO ELLIPTA 50-25 MCG INHALER, manufactured by GlaxoSmithKline LLC, is $6.4820 per EA (NDC 00173091610), effective Sep 30, 2026.
How has the price of BREO ELLIPTA 50-25 MCG INHALER changed over time?
Over the history we have for it, the NADAC for BREO ELLIPTA 50-25 MCG INHALER has held within roughly two percent of its current level. It has been tracked across 124 weekly CMS publications since May 22, 2024.
What are the highest and lowest recorded NADAC prices for BREO ELLIPTA 50-25 MCG INHALER?
Since May 22, 2024, the NADAC for BREO ELLIPTA 50-25 MCG INHALER has ranged from a low of $6.4820 (Sep 23, 2026) to a high of $6.5164 (Jun 12, 2024), with a median of $6.4933 per EA.
Are there cheaper alternatives to BREO ELLIPTA 50-25 MCG INHALER?
No other NADAC-published product currently shares the active ingredient and strength of BREO ELLIPTA 50-25 MCG INHALER in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures BREO ELLIPTA 50-25 MCG INHALER?
BREO ELLIPTA 50-25 MCG INHALER (NDC 00173091610) is labeled by GlaxoSmithKline LLC, and CMS classifies it as a brand product.